YUTREPIA Thrives in PH Space, Eyes $1B Revenue

YUTREPIA is making waves in the inhaled prostacyclin market for pulmonary arterial hypertension and PH-interstitial lung disease, with impressive prescription and sales figures. Their first quarter of 2026 net sales surged by 44% to $129.9 million, marking their third consecutive profitable quarter. Adjusted EBITDA nearly tripled to $71.2 million, and their cash pile grew by 32.1% to $222.8 million. Physicians are switching from competitors due to YUTREPIAs better tolerability, higher dosing, and fewer side effects. The pipeline is strong, with ASCENT Cohort B and Phase III RESPIRE studies underway, and plans for expansions into IPF, PH-COPD, and more. YUTREPIA is on track to reach $1 billion in net revenue by 2027, redefining prostacyclin standards. Support the show:Get a discount at https://solipillow.com/discount/dnn. Advertise on DNN:[email protected] This is an automated, high-level news summary based on public reporting.Report issues to [email protected]. View sources & latest updates:https://sources.thednn.ai/b5c07f4f09e51587